VEINAMINE 8%
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VEINAMINE 8% (VEINAMINE 8%).
VEINAMINE 8% (sulfadiazine) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, disrupting folic acid synthesis and thus bacterial DNA replication.
| Metabolism | Hepatic acetylation (N-acetyltransferase) and glucuronidation; primarily renal excretion. |
| Excretion | Primarily renal; unchanged drug and metabolites excreted in urine (approx. 95%). Biliary/fecal excretion is minimal (<5%). |
| Half-life | Terminal elimination half-life of amino acids is approximately 0.5-1 hour in patients with normal renal function; prolonged in renal impairment. |
| Protein binding | Amino acids are minimally protein-bound (<10%); primarily bound to albumin if any binding occurs. |
| Volume of Distribution | Volume of distribution approximates total body water, ~0.6 L/kg, indicating distribution into extracellular and intracellular spaces. |
| Bioavailability | Bioavailability is 100% by intravenous route; not administered orally due to first-pass metabolism. |
| Onset of Action | Intravenous: Immediate onset of protein synthesis support within minutes; clinical effects on nitrogen balance observed within hours. |
| Duration of Action | Duration of metabolic effect is 4-6 hours following IV infusion; reflects the transient increase in plasma amino acid levels and incorporation into tissues. |
Intravenous infusion: 500 mL to 1 L of 8% solution infused over 8-12 hours; maximum infusion rate 100 mL/hour.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <50 mL/min: reduce dose by 50%; GFR <25 mL/min: avoid use or reduce dose by 75%. |
| Liver impairment | Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: contraindicated. |
| Pediatric use | Intravenous infusion: 2-3 mL/kg/hour, not to exceed 100 mL/hour; total daily dose 20-30 mL/kg. |
| Geriatric use | Start with lower end of dosing range (500 mL over 12 hours); monitor for fluid overload and electrolyte imbalances. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for VEINAMINE 8% (VEINAMINE 8%).
| Breastfeeding | It is unknown whether VEINAMINE 8% is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. M/P ratio not available. |
| Teratogenic Risk | VEINAMINE 8% (branched-chain amino acid solution) has no known teratogenic risk in animal studies; however, adequate human studies in pregnant women are lacking. Use during pregnancy only if clearly needed. The risk to the fetus cannot be ruled out. |
| Fetal Monitoring |
■ FDA Black Box Warning
Sulfonamides have been associated with fatal hypersensitivity reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis. Also, sulfadiazine may cause kernicterus in neonates.
| Serious Effects |
Hypersensitivity to sulfonamides or any component; patients with porphyria; infants <2 months of age (except for treatment of congenital toxoplasmosis); pregnancy at term and nursing mothers due to risk of kernicterus.
| Precautions | May cause severe hypersensitivity reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at first sign of skin rash. Use with caution in patients with renal or hepatic impairment, glucose-6-phosphate dehydrogenase deficiency, or porphyria. Monitor renal function and blood counts during prolonged therapy. |
Loading safety data…
| Monitor maternal vital signs, fluid balance, serum electrolytes, blood urea nitrogen, and ammonia levels. Fetal monitoring should be based on clinical judgment; consider nonstress test or biophysical profile if maternal condition warrants. |
| Fertility Effects | No studies on fertility effects in humans or animals are available. Theoretical amino acid imbalance might affect reproductive function, but no specific data for VEINAMINE 8%. |